Search

The first book-length treatment of scientific freedom as a human right, this book explores the human rights framework as a normatively and intellectually rigorous framework for the balancing of interests, benefits, and harms at the intersection between science and society.

With the advent of robust and high-throughput mass spectrometric technologies and bioinformatics tools to analyze large data sets, proteomics has penetrated broadly into basic and translational life sciences research. More than 95% of FDA-approved drugs currently target proteins, and most diagnostic tests are protein-based. The introduction of proteomics to the clinic, for instance to guide patient stratification and treatment, is already ongoing. Importantly, ethical challenges come with this success, which must also be adequately addressed by the proteomics and medical communities. Consortium members of the H2020 European Union-funded proteomics initiative: European Proteomics Infrastructure Consortium-providing access (EPIC-XS) met at the Core Technologies for Life Sciences (CTLS) conference to discuss the emerging role and implementation of proteomics in the clinic. The discussion, involving leaders in the field, focused on the current status, related challenges, and future efforts required to make proteomics a more mainstream technology for translational and clinical research. Here we report on that discussion and provide an expert update concerning the feasibility of clinical proteomics, the ethical implications of generating and analyzing large-scale proteomics clinical data, and recommendations to ensure both ethical and effective implementation in real-world applications.

How can scientists assist society and contribute to international policymaking – and just as crucially, how can society engage with and shape science? What will it take to make modern science diplomacy for the Anthropocene successful so that the benefits of science are furthered and its risks and harms, as far as possible, prevented? In this article, we explore the relevance and usefulness of three areas of study to these questions: science diplomacy, the human right to science, and anticipation in the context of scientific and technological developments. We argue that a hitherto underappreciated aspect of science diplomacy – diplomacy (with)in science – has significant potential to complement anticipatory approaches such as the Geneva Science and Diplomacy Anticipator's (GESDA's) by furthering the same goals: ameliorating the negative impacts of scientific and technological developments and facilitating their benefits. We relate the concept of diplomacy (with)in science to the normative framework of the right to science under international human rights law and develop and motivate it further by illustrating two potential areas for its application., How can scientists assist society and contribute to internationalpolicymaking–and just as crucially, how can society engage withand shape science? What will it take to make modern sciencediplomacy for the Anthropocene successful so that the benefitsof science are furthered and its risks and harms, as far as possible,prevented?In this article, we explore the relevance and usefulness of threeareas of study to these questions: science diplomacy, the humanright to science, and anticipation in the context of scientific andtechnological developments. We argue that a hithertounderappreciated aspect of science diplomacy–diplomacy(with)in science–has significant potential to complementanticipatory approaches such as the Geneva Science andDiplomacy Anticipator’s (GESDA’s) by furthering the same goals:ameliorating the negative impacts of scientific and technologicaldevelopments and facilitating their benefits. We relate theconcept of diplomacy (with)in science to the normativeframework of the right to science under international humanrights law and develop and motivate it further by illustrating twopotential areas for its application.

With the advent of robust and high-throughput mass spectrometric technologies and bioinformatics tools to analyze large data sets, proteomics has penetrated broadly into basic and translational life sciences research. More than 95% of FDA-approved drugs currently target proteins, and most diagnostic tests are protein-based. The introduction of proteomics to the clinic, for instance to guide patient stratification and treatment, is already ongoing. Importantly, ethical challenges come with this success, which must also be adequately addressed by the proteomics and medical communities. Consortium members of the H2020 European Union-funded proteomics initiative: European Proteomics Infrastructure Consortium-providing access (EPIC-XS) met at the Core Technologies for Life Sciences (CTLS) conference to discuss the emerging role and implementation of proteomics in the clinic. The discussion, involving leaders in the field, focused on the current status, related challenges, and future efforts required to make proteomics a more mainstream technology for translational and clinical research. Here we report on that discussion and provide an expert update concerning the feasibility of clinical proteomics, the ethical implications of generating and analyzing large-scale proteomics clinical data, and recommendations to ensure both ethical and effective implementation in real-world applications.